Quince Therapeutics, Inc.

IRLA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 81.9%, free cash flow fell 63.7% and total debt rose 28.2%, each against the same quarter a year earlier.

32.17 1.06 −3.19%
Market cap
$33.8M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
14.52 2.92 0.53 1.12

+8 more quarters

Net Debt/EBITDA
1.45 1.24 (0.03) 0.64
Debt/Assets
0.00% 0.00% 19.63% 15.94%
Debt/Equity
0.00 0.00 (0.51) 16.54
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.25 (0.21) 0.27 0.74
Capex/Depreciation
0.00 0.00 0.03 0.37
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.73 0.62
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(3.08) (16.73) (41.86) (37.07)
Cash per Share
18.91 39.83 70.87 97.44
Shareholders Equity per Share
(5.76) 34.37 (142.57) 3.93
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(5.76) 34.37 (142.57) 3.93
Free Cash Flow
(18.89) (7.63) (10.48) (10.00)
Working Capital
114.91 16.81 (20.33) 3.16
Capital Expenditures
— — 0.00 (0.07)
Net Current Asset Value
(35.91) 14.63 (106.34) (79.64)
Other line items
Quick Ratio
13.64 2.07 0.41 1.01
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(3.08) (16.73) (41.84) (36.80)
Capex per Share
0.00 0.00 (0.02) (0.27)
Average Payables
3.20 4.20 2.56 2.51
Average Assets
120.60 66.86 104.00 118.21
Average Common Equity
(11.79) 17.13 (2.78) 23.00
Capex to Sales
— — 0.00 0.00

Fold the line items

Columns are period end dates